Business / Finance

RSS

Samsung BioLogics celebrates groundbreaking of new biopharmaceutical manufacturing plant in Korea

Samsung BioLogics today celebrated the groundbreaking of its third plant in Incheon Free Economic Zone, Songdo, Korea. Joining the event were Samsung Electronics Vice Chairman Jay Y. Lee, Samsung BioLogics President & CEO Dr. TH Kim and over 500 attendees.

21 Dec 2015

Univercells awarded grant to reduce cost of vaccine manufacturing in the Walloon region

Univercells SA, a company that designs single-use cost-efficient bioprocess solutions for the next generation of biomanufacturing, today announces that it has received a grant from the Walloon region.

21 Dec 2015

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200.

20 Dec 2015

GSI Group purchases SkyeTek assets for $2.6 million

GSI Group Inc., a global leader and supplier of laser, precision motion, and vision technologies to original equipment manufacturers ("OEM") in the medical and advanced industrial markets, today announced it has acquired the assets of SkyeTek, a Denver, Colorado-based provider of embedded and standalone RFID Solutions for medical OEM's for $2.6 million in cash, subject to customary working capital adjustments.

20 Dec 2015

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

Janssen Pharmaceuticals, Inc. announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen's own AdVac® technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.

20 Dec 2015

ALPHAEON announces acquisition of Rocol SA

ALPHAEON Corporation, a social commerce company and subsidiary to Strathspey Crown Holdings LLC, today announced its acquisition of Rocol SA, a leader in the commercialization of medical equipment across Latin America. Terms of the acquisition were not disclosed.

18 Dec 2015

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

The Medicines Patent Pool today announced a new licensing agreement with AbbVie, a global biopharmaceutical company, that seeks to address future demands for HIV treatment Lopinavir/Ritonavir (LPV/r) in South Africa and across Africa. The agreement has been reached in particular to help ensure sustainability of long-term supply of LPV/r, the most widely used second-line HIV treatment in South Africa and across Africa.

18 Dec 2015

Perrigo to acquire generic Retin-A portfolio from Matawan Pharmaceuticals

Perrigo Company plc announced today that it will acquire a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, LLC. Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated.

17 Dec 2015

ChemicalInfo partners with e-samples to accelerate sample ordering process for CIS Subscribers

ChemicalInfo, providers of the most comprehensive online databases for chemical and pharmaceutical companies and those who do business with them, announces partnership with e-samples, a comprehensive database offering integrated solutions for samples and development product supply chain processes.

17 Dec 2015

ALPHAEON completes acquisition of LENSAR

ALPHAEON Corporation, a social commerce company and subsidiary to Strathspey Crown Holdings LLC, today announced it has closed on its acquisition of LENSAR, Inc., a leading global developer and manufacturer of Femtosecond Lasers Systems (FLS), through a wholly owned subsidiary. Terms of the acquisition were not disclosed.

17 Dec 2015

WuXi forms strategic alliance with MedImmune to accelerate development of biologics portfolio in China

WuXi AppTec, a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that it has formed a strategic alliance with MedImmune, the global biologics research and development arm of AstraZeneca.

16 Dec 2015

CytoSorbents partners with Hoang Long Pharma to bring CytoSorb to Vietnam

CytoSorbents Corporation, a leader in critical care immunotherapy commercializing its CytoSorb extracorporeal cytokine adsorber to control deadly inflammation using blood purification, today announced an exclusive multi-year distribution agreement with Hoang Long Pharma, a medical distributor in Vietnam specializing in the distribution of innovative pharmaceuticals, biologics, and devices to treat patients suffering from critical illnesses, immunologic disorders and deficiencies, and infections.

15 Dec 2015

ALPHAEON agrees to bring Zelegent's office-based Elevoplasty technology to sleep specialists

ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Zelegent, Inc. jointly announced today that the two companies have entered into an exclusive worldwide agreement to bring Zelegent's office-based Elevoplasty technology to board certified sleep specialists.

15 Dec 2015

Honeywell acquires Sigma-Aldrich's laboratory research chemicals business

Honeywell today announced that it has completed the acquisition of the Seelze, Germany-based laboratory research chemicals business from Sigma-Aldrich, broadening Honeywell's offerings for high-purity solutions for drug discovery, medical diagnostic testing and other laboratory applications.

15 Dec 2015

ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA Pharma Inc. today reported financial results for the year ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with International Financial Reporting Standards ("IFRS").

15 Dec 2015

Viralytics announces completion of $28 million placement

Viralytics Limited announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736.

14 Dec 2015

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Validus Pharmaceuticals LLC, together with Wood Creek Capital Management, LLC ("Wood Creek"), announced today the acquisition of the U.S. rights to several well-known product lines from Sanofi US: Anzemet (dolasetron mesylate) Injection and Tablets, Claforan (cefotaxime) Injection/IM/IV, Demerol (meperidine hydrochloride) Tablets, Drisdol (ergocalciferol) Capsules and Oral Solution, Hiprex (methenamine hippurate) Tablets, Lasix (furosemide) Tablets, Norpramin (desipramine hydrochloride) Tablets and Trental (pentoxifylline) Tablets.

14 Dec 2015

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies, for the treatment of cancer and severe autoimmune diseases, announces that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease.

14 Dec 2015

CTI BioPharma earns $10 million milestone payment from Teva for TRISENOX (arsenic trioxide)

CTI BioPharma Corp. today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX (arsenic trioxide).

14 Dec 2015

Business / Finance

Samsung BioLogics celebrates groundbreaking of new biopharmaceutical manufacturing plant in Korea

Univercells awarded grant to reduce cost of vaccine manufacturing in the Walloon region

Variant signs worldwide exclusive license and development agreement with L&F Research

GSI Group purchases SkyeTek assets for $2.6 million

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

ALPHAEON announces acquisition of Rocol SA

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

Perrigo to acquire generic Retin-A portfolio from Matawan Pharmaceuticals

ChemicalInfo partners with e-samples to accelerate sample ordering process for CIS Subscribers

ALPHAEON completes acquisition of LENSAR

WuXi forms strategic alliance with MedImmune to accelerate development of biologics portfolio in China

CytoSorbents partners with Hoang Long Pharma to bring CytoSorb to Vietnam

ALPHAEON agrees to bring Zelegent's office-based Elevoplasty technology to sleep specialists

Honeywell acquires Sigma-Aldrich's laboratory research chemicals business

ESSA reports net loss of $11.5 million for year ended September 30, 2015

Viralytics announces completion of $28 million placement

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

CTI BioPharma earns $10 million milestone payment from Teva for TRISENOX (arsenic trioxide)

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Latest News